About AVEO Pharmaceuticals (NASDAQ:AVEO)
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company's pipeline of product candidates include Tivozanib, a vascular endothelial growth factor (VEGF) to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. Its development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension. The company has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; and Kyowa Hakko Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:AVEO
CUSIP05358810
Phone617-588-1960
Debt
Debt-to-Equity Ratio-0.45%
Current Ratio1.56%
Quick Ratio1.56%
Price-To-Earnings
Trailing P/E Ratio-16.19
Forward P/E Ratio-9.59
P/E GrowthN/A
Sales & Book Value
Annual Sales$7.58 million
Price / Sales40.62
Cash FlowN/A
Price / CashN/A
Book Value($0.34) per share
Price / Book-7.62
Profitability
EPS (Most Recent Fiscal Year)($0.16)
Net Income$-65,020,000.00
Net Margins-857.96%
Return on EquityN/A
Return on Assets-41.17%
Miscellaneous
Employees19
Outstanding Shares118,870,000
AVEO Pharmaceuticals (NASDAQ:AVEO) Frequently Asked Questions
What is AVEO Pharmaceuticals' stock symbol?
AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."
How were AVEO Pharmaceuticals' earnings last quarter?
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced its earnings results on Thursday, May, 4th. The biopharmaceutical company reported ($0.12) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.12) by $0.00. The biopharmaceutical company had revenue of $2.53 million for the quarter. View AVEO Pharmaceuticals' Earnings History.
What price target have analysts set for AVEO?
4 Wall Street analysts have issued 12-month price targets for AVEO Pharmaceuticals' shares. Their forecasts range from $3.00 to $5.00. On average, they anticipate AVEO Pharmaceuticals' stock price to reach $4.1667 in the next twelve months. View Analyst Ratings for AVEO Pharmaceuticals.
Who are some of AVEO Pharmaceuticals' key competitors?
Some companies that are related to AVEO Pharmaceuticals include Reata Pharmaceuticals (RETA), BeyondSpring (BYSI), Rhythm Pharmaceuticals (RYTM), Ziopharm Oncology (ZIOP), AC Immune (ACIU), Arrowhead Pharmaceuticals (ARWR), Rigel Pharmaceuticals (RIGL), Geron (GERN), Clementia Pharmaceuticals (CMTA), Odonate Therapeutics (ODT), Achaogen (AKAO), Keryx Biopharmaceuticals (KERX), Aduro BioTech (ADRO), Five Prime Therapeutics (FPRX), Kura Oncology (KURA), TiGenix - American Depositary Shares (TIG), Aclaris Therapeutics (ACRS) and ChemoCentryx (CCXI).
Who are AVEO Pharmaceuticals' key executives?
AVEO Pharmaceuticals' management team includes the folowing people:
- Mr. Michael P. Bailey, Pres, CEO & Director (Age 53)
- Dr. Michael N. Needle M.D., Chief Medical Officer (Age 58)
- Mr. Matthew D. Dallas, Chief Financial Officer (Age 43)
- Dr. Emile Farhan Ph.D., VP of Technical Operations
- Ms. Karuna Rubin J.D., VP of Legal Affairs and Corp. Sec.
Has AVEO Pharmaceuticals been receiving favorable news coverage?
Media stories about AVEO stock have trended somewhat positive on Saturday, according to Accern. The research firm rates the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. AVEO Pharmaceuticals earned a media sentiment score of 0.12 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 48.08 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
How do I buy shares of AVEO Pharmaceuticals?
Shares of AVEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AVEO Pharmaceuticals' stock price today?
One share of AVEO stock can currently be purchased for approximately $2.59.
How big of a company is AVEO Pharmaceuticals?
AVEO Pharmaceuticals has a market capitalization of $315 million and generates $7.58 million in revenue each year. The biopharmaceutical company earns $-65,020,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. AVEO Pharmaceuticals employs 19 workers across the globe.
How can I contact AVEO Pharmaceuticals?
AVEO Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-588-1960 or via email at [email protected]
MarketBeat Community Rating for AVEO Pharmaceuticals (AVEO)
MarketBeat's community ratings are surveys of what our community members think about AVEO Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVEO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVEO will underperform the S&P 500 over the long term. You may vote once every thirty days.
AVEO Pharmaceuticals (NASDAQ:AVEO) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for AVEO Pharmaceuticals in the last 12 months. Their average twelve-month price target is $4.1667, suggesting that the stock has a possible upside of 60.88%. The high price target for AVEO is $5.00 and the low price target for AVEO is $3.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $4.1667 | $4.1667 | $4.1667 | $3.75 |
| Price Target Upside: | 60.88% upside | 34.41% upside | 34.41% upside | 5.06% downside |
AVEO Pharmaceuticals (NASDAQ:AVEO) Consensus Price Target History
AVEO Pharmaceuticals (NASDAQ:AVEO) Analyst Ratings History
Show:
(Data available from 4/21/2016 forward)
AVEO Pharmaceuticals (NASDAQ:AVEO) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
AVEO Pharmaceuticals (NASDAQ AVEO) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.70%
Institutional Ownership Percentage: 51.58%
AVEO Pharmaceuticals (NASDAQ AVEO) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/10/2018 | Peter J Barris | Major Shareholder | Buy | 920,976 | $2.30 | $2,118,244.80 | |  |
| 4/6/2018 | Ravi Viswanathan | Major Shareholder | Buy | 685,676 | $2.24 | $1,535,914.24 | | |
| 3/28/2017 | Equity Opportunities Iv Growth | Major Shareholder | Buy | 6,000,000 | $0.50 | $3,000,000.00 | | |
| 1/16/2015 | Matthew D Dallas | VP | Sell | 3,075 | $0.82 | $2,521.50 | | |
| 1/7/2015 | Michael P Bailey | CEO | Sell | 4,484 | $0.80 | $3,587.20 | | |
| 1/30/2014 | Joseph Vittiglio | SVP | Sell | 5,430 | $1.64 | $8,905.20 | 34,121 | |
| 3/14/2013 | David Brannon Johnston | CFO | Sell | 1,061 | $7.34 | $7,787.74 | | |
| 3/7/2013 | Henri A Termeer | Director | Buy | 55,499 | $6.73 | $373,508.27 | | |
| 12/13/2012 | Ngoc Tuan Ha | CEO | Buy | 75,000 | $6.65 | $498,750.00 | | |
| 12/13/2012 | Robert C Young | Director | Buy | 2,371 | $6.78 | $16,075.38 | | |
| 12/3/2012 | Robert C Young | Director | Buy | 1,250 | $6.41 | $8,012.50 | | |
| 9/13/2012 | David Brannon Johnston | CFO | Sell | 1,386 | $10.60 | $14,691.60 | | |
| 8/8/2012 | Robert C Young | Director | Buy | 1,000 | $8.63 | $8,630.00 | | |
(Data available from 1/1/2013 forward)
AVEO Pharmaceuticals (NASDAQ AVEO) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Ex-Aveo Pharmaceuticals CFO must face SEC trial, judge rules
www.reuters.com - April 21 at 8:19 AM |
| SEC seeks to block ex-Aveo CFO's testimony about consulting counsel
www.reuters.com - April 19 at 8:16 AM |
 | AVEO Pharmaceuticals (AVEO) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 16 at 9:17 PM |
 | AVEO Down 7.7% Since Earnings Report: Can It Rebound?
finance.yahoo.com - April 12 at 5:39 PM |
 | AVEO Pharmaceuticals (AVEO) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 11 at 5:32 PM |
| AVEO Pharmaceuticals' (AVEO) Buy Rating Reiterated at Piper Jaffray
www.americanbankingnews.com - April 10 at 10:31 PM |
| Insider Buying: AVEO Pharmaceuticals, Inc. (AVEO) Major Shareholder Acquires 685,676 Shares of Stock
www.americanbankingnews.com - April 10 at 7:30 PM |
| Peter J. Barris Purchases 920,976 Shares of AVEO Pharmaceuticals, Inc. (AVEO) Stock
www.americanbankingnews.com - April 10 at 7:12 PM |
| Why AVEO Oncology Jumped Higher Today
finance.yahoo.com - April 9 at 5:22 PM |
| Moving Average Crossover Alert: AVEO Pharmaceuticals, Inc. (AVEO)
finance.yahoo.com - April 5 at 10:10 AM |
| Zacks: Brokerages Anticipate AVEO Pharmaceuticals, Inc. (AVEO) to Post -$0.07 EPS
www.americanbankingnews.com - April 2 at 9:12 AM |
| AVEO Pharmaceuticals (AVEO) Downgraded by BidaskClub
www.americanbankingnews.com - March 30 at 9:17 AM |
| AVEO Pharmaceuticals, Inc. (AVEO) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - March 30 at 1:34 AM |
| AVEO Pharmaceuticals (AVEO) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - March 29 at 11:18 PM |
| AVEO Pharmaceuticals (AVEO) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 29 at 5:30 PM |
| AVEO Pharmaceuticals (AVEO) Rating Reiterated by B. Riley
www.americanbankingnews.com - March 28 at 12:58 PM |
| AVEO Pharmaceuticals (AVEO) Upgraded to "Sell" by BidaskClub
www.americanbankingnews.com - March 26 at 5:58 PM |
| AVEO Pharmaceuticals (AVEO) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - March 25 at 12:52 AM |
| AVEO Pharmaceuticals (AVEO) Rating Increased to Sell at BidaskClub
www.americanbankingnews.com - March 24 at 10:58 AM |
| Options Traders Expect Huge Moves in AVEO Pharmaceuticals (AVEO) Stock
finance.yahoo.com - March 23 at 5:42 PM |
| AVEO Oncology Announces Publication of Long-term Follow-up Results from TIVO-1 Extension Study (Study 902) in TKI Refractory RCC
finance.yahoo.com - March 21 at 5:38 PM |
| AVEO Pharmaceuticals (AVEO) Q4 Loss Widens, Shares Down - Yahoo Finance
finance.yahoo.com - March 16 at 8:19 AM |
| -$0.06 EPS Expected for AVEO Pharmaceuticals, Inc. (AVEO) This Quarter
www.americanbankingnews.com - March 16 at 7:33 AM |
| Q3 2018 EPS Estimates for AVEO Pharmaceuticals, Inc. Cut by B. Riley (AVEO)
www.americanbankingnews.com - March 15 at 8:15 AM |
| AVEO Pharmaceuticals, Inc. Forecasted to Earn Q1 2019 Earnings of ($0.05) Per Share (AVEO)
www.americanbankingnews.com - March 14 at 12:56 PM |
| BRIEF-Aveo Quarterly Loss Per Share $0.08
www.reuters.com - March 13 at 7:17 PM |
| AVEO Pharmaceuticals (AVEO) Q4 Loss Wider, Revenues Miss
finance.yahoo.com - March 13 at 7:17 PM |
| AVEO Reports Full Year 2017 Financial Results and Provides Business Update
finance.yahoo.com - March 13 at 8:25 AM |
| AVEO posts 4Q profit
finance.yahoo.com - March 13 at 8:25 AM |
 | Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of AVEO ... - PR Newswire (press release)
www.prnewswire.com - March 9 at 8:20 AM |
 | AVEO Pharmaceuticals' (AVEO) Q4 Earnings: What's in Store?
www.msn.com - March 6 at 5:41 PM |
| AVEO Pharmaceuticals' (AVEO) Q4 Earnings: What's in Store?
finance.yahoo.com - March 6 at 5:41 PM |
| AVEO Oncology to Present at the Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - March 6 at 8:15 AM |
| Prosight Management LP Purchases New Holdings in AVEO Pharmaceuticals, Inc. (AVEO)
www.americanbankingnews.com - March 5 at 2:54 PM |
| AVEO Pharmaceuticals, Inc. (AVEO) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - March 5 at 1:30 AM |
| Emory University Acquires Shares of 602,883 AVEO Pharmaceuticals, Inc. (AVEO)
www.americanbankingnews.com - March 4 at 3:02 PM |
| EAM Investors LLC Sells 158,839 Shares of AVEO Pharmaceuticals, Inc. (AVEO)
www.americanbankingnews.com - March 3 at 5:40 AM |
| Zai Lab (ZLAB) vs. AVEO Pharmaceuticals (AVEO) Head-To-Head Analysis
www.americanbankingnews.com - February 12 at 11:36 AM |
| Ex-Aveo Pharmaceuticals exec avoids max penalty in SEC fraud case
www.reuters.com - February 10 at 9:43 AM |
| AVEO Pharmaceuticals, Inc. (AVEO) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - February 8 at 1:32 AM |
| AVEO Announces Appointment of John H. Johnson to Board of Directors
finance.yahoo.com - February 2 at 9:19 AM |
| How Much is AVEO Pharmaceuticals Inc’s (NASDAQ:AVEO) CEO Getting Paid?
finance.yahoo.com - January 26 at 9:08 AM |
| Biotech Forum Daily Digest For January 21st - Seeking Alpha
seekingalpha.com - January 24 at 8:06 AM |
| Blog Exposure - AVEO Pharma Presents Data from Phase-1b/2 Study of Tivozanib in Patients with Advanced HCC
finance.yahoo.com - January 23 at 5:26 PM |
| Ex-Aveo Pharmaceuticals exec fights SEC 'draconian' penalty request
www.reuters.com - January 18 at 4:24 PM |
| AVEO Pharmaceuticals, Inc. (AVEO) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 14 at 1:32 AM |
 | Here's Why AVEO Oncology Rose as Much as 13.7% Today - Motley Fool
www.fool.com - January 13 at 3:39 PM |
| Here's Why AVEO Oncology Rose as Much as 13.7% Today
finance.yahoo.com - January 13 at 11:05 AM |
| AVEO Oncology to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 11:11 AM |
| SEC seeks penalty, 5-year ban for ex-Aveo Pharmaceuticals exec
www.reuters.com - January 2 at 9:13 PM |
AVEO Pharmaceuticals (NASDAQ:AVEO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
AVEO Pharmaceuticals (NASDAQ:AVEO) Income Statement, Balance Sheet and Cash Flow Statement
AVEO Pharmaceuticals (NASDAQ AVEO) Stock Chart for Saturday, April, 21, 2018
Loading chart…
